<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978793</url>
  </required_header>
  <id_info>
    <org_study_id>1399864-6</org_study_id>
    <nct_id>NCT03978793</nct_id>
  </id_info>
  <brief_title>MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence Among HIV+ Prescription Opioid Users</brief_title>
  <acronym>MyTPill</acronym>
  <official_title>MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence Among HIV+ Prescription Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fenway Community Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fenway Community Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares several different antiretroviral adherence measures, including digital
      pills, in HIV+ individuals who are maintained on opioid analgesics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares digital pills, electronic pill bottles, self-report, and dried blood
      spots, in measuring adherence to antiretroviral medications containing emtricitabine and
      tenofovir. The study sites are Jackson Memorial Hospital and Fenway Community Health.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover study design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dried blood spots</measure>
    <time_frame>six months</time_frame>
    <description>Measurement of dried blood spots for TDF and FTC concentrations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV-positive Individuals</condition>
  <arm_group>
    <arm_group_label>MyTPill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive digital pills for three months, have a 2-week washout, then switch to Wisepill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wisepill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Wisepill for three months, have a 2-week washout, then switch to digital pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MyTPill, a digital pill</intervention_name>
    <description>MyTPill is a digital pill containing an approved medication</description>
    <arm_group_label>MyTPill</arm_group_label>
    <arm_group_label>Wisepill</arm_group_label>
    <other_name>Wisepill, a digital pillbox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+, Viral load &gt;200copies/mL, on single pill containing TDF/FTC, receiving
             prescription for opioid analgesics

        Exclusion Criteria:

          -  Severe renal or hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edward W Boyer, MD</last_name>
    <phone>617 927-6400</phone>
    <email>eboyer@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam Carrico, PhD</last_name>
    <email>acarrico@miami.edu</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fenway Community Health</investigator_affiliation>
    <investigator_full_name>Ed Boyer</investigator_full_name>
    <investigator_title>Adjunct Faculty</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

